Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Petru, E; Andel, J; Angleitner-Boubenizek, L; Steger, G; Bernhart, M; Busch, K; Gehmacher, O; Hernler, T; Kastner, U; Lanz-Veit, A; Pluschnigg, U; Polachova, J; Rohde, M; Schiller, L; Schramböck, R; Stangl, W; Thödtmann, R; Zabernigg, A.
Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy.
Wien Med Wochenschr. 2008; 158(5-6): 169-173.
Doi: 10.1007/s10354-008-0515-1
PubMed
FullText
FullText_MUG
Google Scholar
- Leading authors Med Uni Graz
- Petru Edgar
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Palonosetron is a new generation 5-HT3-receptor antagonist with a significantly prolonged half-life and a once-a-day administration compared to the conventional setrons. To evaluate the antiemetic efficacy of palonosetron in the daily hospital practice setting, a postmarketing study was carried out in Austria. METHODS: Palonosetron was administered at 0.25 mg on day 1 of each cycle to 135 cancer patients who received moderately or highly emetogenic chemotherapy either as an IV bolus or as a short-term infusion. Two thirds of these patients were females (n = 90), the majority had breast cancer (n = 38) and the majority received cisplatin, carboplatin, anthracyclines, 5-fluorouracil or cyclophosphamide. RESULTS: The complete antiemetic response rate was 68 % overall with 87 % efficacy on day 1 and 72 % efficacy on days 2 to 5. Higher antiemetic response was achieved in male patients, in patients being aged > or = 50 years, and in chemonaive patients. Twenty-four percent of patients needed rescue medication. Only 1.5 % of patients reported mild adverse events. CONCLUSIONS: Palonosetron resulted in high antiemetic efficacy in this study. Female gender and age < or = 50 years should be particularly considered when the antiemetic regimen is selected.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Age Factors -
- Aged -
- Antiemetics - administration and dosage
- Antineoplastic Agents - adverse effects
- Austria - adverse effects
- Breast Neoplasms - drug therapy
- Cancer Care Facilities - drug therapy
- Female - drug therapy
- Humans - drug therapy
- Isoquinolines - administration and dosage
- Male - administration and dosage
- Middle Aged - administration and dosage
- Nausea - chemically induced
- Neoplasms - drug therapy
- Practice Guidelines as Topic - drug therapy
- Product Surveillance, Postmarketing - drug therapy
- Questionnaires - drug therapy
- Quinuclidines - administration and dosage
- Receptors, Serotonin, 5-HT3 - antagonists and inhibitors
- Serotonin Antagonists - administration and dosage
- Sex Factors - administration and dosage
- Time Factors - administration and dosage
- Vomiting - chemically induced